Fig. 2

Stroke risk and stroke prevention in atrial fibrillation patients with CKD. a Comparison of stroke risk in each group. The proportion of high stroke risk was higher in the CKD group than in the normal group (94.9% vs. 67.0%, p < 0.001). b Comparison of oral anticoagulant medication in each group. The CKD group had a higher usage rate of NOAC than the normal group (61.1% vs. 47.8%, p = 0.001). c Comparison of NOAC in each group. Among NOACs, apixaban was most frequently used in CKD patients compared with controls (32.6% vs. 18.4, p = 0.001). CKD, chronic kidney disease; NOAC, non-vitamin K oral anticoagulant. Asterisks indicate that the percentage was different between the groups